FY2028 Earnings Estimate for Disc Medicine Issued By Wedbush

Disc Medicine, Inc. (NASDAQ:IRON) – Stock analysts at Wedbush upped their FY2028 EPS estimates for shares of Disc Medicine in a research note issued on Wednesday, October 22nd. Wedbush analyst D. Nierengarten now expects that the company will earn $1.79 per share for the year, up from their previous forecast of $1.64. Wedbush has a “Outperform” rating and a $110.00 price target on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.41).

A number of other analysts also recently weighed in on IRON. National Bankshares set a $153.00 price target on shares of Disc Medicine in a research report on Friday, October 17th. HC Wainwright reiterated a “buy” rating and issued a $118.00 price target on shares of Disc Medicine in a research report on Thursday, July 3rd. Raymond James Financial increased their price target on shares of Disc Medicine from $89.00 to $108.00 and gave the company a “strong-buy” rating in a research report on Friday, October 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a research report on Friday. Finally, Morgan Stanley increased their target price on Disc Medicine from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Monday, August 18th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Disc Medicine presently has an average rating of “Moderate Buy” and a consensus price target of $110.70.

Disc Medicine Stock Performance

Shares of NASDAQ:IRON opened at $85.63 on Friday. The company has a market capitalization of $2.98 billion, a price-to-earnings ratio of -19.16 and a beta of 0.80. The firm’s 50 day simple moving average is $66.30 and its 200 day simple moving average is $56.24. The company has a debt-to-equity ratio of 0.05, a current ratio of 32.11 and a quick ratio of 32.11. Disc Medicine has a fifty-two week low of $30.82 and a fifty-two week high of $95.95.

Insider Transactions at Disc Medicine

In other news, Director Kevin Bitterman sold 70,000 shares of the firm’s stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $88.91, for a total transaction of $6,223,700.00. Following the completion of the transaction, the director directly owned 385,549 shares of the company’s stock, valued at $34,279,161.59. This trade represents a 15.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders sold 226,933 shares of company stock worth $17,005,801. 3.64% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Disc Medicine

Several hedge funds have recently made changes to their positions in IRON. RA Capital Management L.P. bought a new position in shares of Disc Medicine during the 1st quarter worth approximately $78,288,000. Siren L.L.C. bought a new position in shares of Disc Medicine during the 1st quarter worth approximately $53,207,000. Wellington Management Group LLP grew its stake in shares of Disc Medicine by 67.9% in the first quarter. Wellington Management Group LLP now owns 2,343,499 shares of the company’s stock valued at $116,331,000 after buying an additional 948,094 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Disc Medicine by 22.2% in the first quarter. Vanguard Group Inc. now owns 1,305,046 shares of the company’s stock valued at $64,782,000 after buying an additional 236,800 shares in the last quarter. Finally, Sio Capital Management LLC grew its stake in shares of Disc Medicine by 287.4% in the second quarter. Sio Capital Management LLC now owns 284,787 shares of the company’s stock valued at $15,082,000 after buying an additional 211,276 shares in the last quarter. 83.70% of the stock is owned by institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.